New GLP-1 analysis reveals that by addressing real-world barriers to persistence, Omada’s companion program can help sustain GLP-1 use, delivering on clinical trials' promises SAN FRANCISCO, June 17, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, released new data 1 demonstrating that Omada’s GLP-1 companion program significantly improved persistence rates for GLP-1... Read More